Table 3.
The representatives of clinical trials of new small molecules targeting dementia.
| Small Molecule | Mechanism of Action | Clinical Trials ID | Condition or Disease |
|---|---|---|---|
| HT-0712 | Phosphodiesterase 4 inhibitor | NCT02013310 | age-associated memory impairment |
| BPN14770 | Phosphodiesterase 4 inhibitor |
NCT02648672 NCT0303010 NCT02840279 |
safety, tolerability, and pharmacokinetic profile |
| PF-04447943 | Phosphodiesterase 9 inhibitor |
NCT00988598 NCT00930059 |
cognitive and behavioral symptoms of AD |
| BI 409306 | Phosphodiesterase 9 inhibitor |
NCT02392468 NCT02337907 |
cognitive impairment due to AD |
| Intepirdine | Selective 5-HT6 receptor antagonist | NCT02586909 | long-term safety and tolerability in LBD |
| Nelotanserin | 5-HT2A inverse agonist | NCT02871427 | long-term safety and tolerability in LBD |
| Ramelteon | Melatonin receptors MT1 and MT2 selective agonist | NCT00325728 | mild-to-moderate AD |
| Bosutinib | Tyrosine kinases Abl/Src dual inhibitor | NCT03888222 | safety, tolerability, biomarkers in LBD |
| Nilotinib | Abl tyrosine kinase inhibitor | NCT04002674 | safety, tolerability, biomarkers in LBD |
| Irsenontrine | Phosphodiesterase 9 inhibitor | NCT03467152 | safety, tolerability, biomarkers in LBD |
| Pimavanserin | 5-HT2A inverse agonist | NCT03325556 | dementia-related psychosis |
| Neflamapimod | p38 mitogen-activated protein (MAP) kinase inhibitor | NCT04001517 | cognitive effects in LBD |